Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy

被引:0
|
作者
Daniel P. Judge
David A. Kass
W. Reid Thompson
Kathryn R. Wagner
机构
[1] Johns Hopkins University,Division of Cardiology/Medicine
[2] Hugo W. Moser Research Institute at Kennedy Krieger,Department of Biomedical Engineering
[3] Université Paris Descartes,Division of Cardiology/Pediatrics
[4] Sorbonne Paris Cité,Department of Neurology
[5] Johns Hopkins University,undefined
[6] Johns Hopkins University,undefined
[7] Johns Hopkins University,undefined
关键词
Losartan; Carvedilol; Duchenne Muscular Dystrophy; Cardiac Dysfunction; Perindopril;
D O I
暂无
中图分类号
学科分类号
摘要
Cardiac dysfunction is a frequent manifestation of Duchenne muscular dystrophy (DMD) and a common cause of death for individuals with this condition. Early diastolic dysfunction and focal fibrosis proceed to dilated cardiomyopathy (DCM), complicated by heart failure and arrhythmia in most patients. Improvements in the management of respiratory insufficiency in DMD have improved lifespan and overall prognosis, but heart failure and sudden death continue to impact survival and quality of life for people with DMD. Since the specific mechanisms resulting in heart failure for people with DMD are poorly understood, current treatments are not targeted, but rely on approaches that are considered standard for DCM. These approaches include angiotensin-converting enzyme (ACE) inhibitors and β-adrenoceptor antagonists. Data from one trial in DMD support the use of ACE inhibitors before the onset of left ventricular dysfunction. Angiotensin receptor blockers have shown similar efficacy to ACE inhibitors in numerous studies of dilated cardiomyopathy, and are a good choice for patients who cannot tolerate ACE inhibition. The pathogenesis of DMD-associated cardiomyopathy may be similar to other genetic disorders of the cytoskeletal complex of ventricular myocytes, though unique features offer targeted opportunities to impact treatment. Novel areas of investigation are focused on the regulatory role of dystrophin in relation to neuronal nitric oxide synthase (nNOS) and transient receptor potential canonical channels (TRPC). Inhibition of phosphodiesterase-5 (PDE5) addresses several aspects of regulatory dysfunction induced by dystrophin deficiency, and studies with PDE5-inhibitors have shown benefits in murine models of DMD. PDE5-inhibitors are currently under investigation in at least one study in humans. This article focuses on mechanisms of cardiac dysfunction, as well as potential targets for pharmacologic manipulation to prevent or improve cardiomyopathy in DMD.
引用
收藏
页码:287 / 294
页数:7
相关论文
共 50 条
  • [41] Gene therapy for Duchenne muscular dystrophy
    Ramos, Julian
    Chamberlain, Jeffrey S.
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1255 - 1266
  • [42] Gene Therapy for Duchenne Muscular Dystrophy
    Elangkovan, Nertiyan
    Dickson, George
    [J]. JOURNAL OF NEUROMUSCULAR DISEASES, 2021, 8 : S303 - S316
  • [43] Duchenne Muscular Dystrophy Gene Therapy
    Saad, Fawzy A.
    Saad, Jasen F.
    Siciliano, Gabriele
    Merlini, Luciano
    Angelini, Corrado
    [J]. CURRENT GENE THERAPY, 2024, 24 (01) : 17 - 28
  • [44] Diagnosis and therapy of Duchenne muscular dystrophy
    Vry, J.
    Schara, U.
    Lutz, S.
    Kirschner, J.
    [J]. MONATSSCHRIFT KINDERHEILKUNDE, 2012, 160 (02) : 177 - 185
  • [45] Occupational Therapy and Duchenne Muscular Dystrophy
    Barratt, Sarah J.
    [J]. INTERNATIONAL JOURNAL OF THERAPY AND REHABILITATION, 2008, 15 (05): : 220 - 220
  • [46] Gene therapy for Duchenne muscular dystrophy
    Verhaart, Ingrid E. C.
    Aartsma-Rus, Annemieke
    [J]. CURRENT OPINION IN NEUROLOGY, 2012, 25 (05) : 588 - 596
  • [47] Progress in therapy for Duchenne muscular dystrophy
    Fairclough, Rebecca J.
    Bareja, Akshay
    Davies, Kay E.
    [J]. EXPERIMENTAL PHYSIOLOGY, 2011, 96 (11) : 1101 - 1113
  • [48] Gene therapy of Duchenne muscular dystrophy
    Dickson, G
    [J]. CHEMISTRY & INDUSTRY, 1996, (08) : 294 - 297
  • [49] Utrophin therapy for Duchenne muscular dystrophy?
    Nelson, R
    [J]. LANCET NEUROLOGY, 2004, 3 (11): : 637 - 637
  • [50] Gene therapy in Duchenne muscular dystrophy
    Inui, K
    Okada, S
    Dickson, G
    [J]. BRAIN & DEVELOPMENT, 1996, 18 (05): : 357 - 361